Skip to main content
. 2023 May 3;14(23):6149–6206. doi: 10.1039/d2sc06665c

Examples of commercial molecular diagnostic assays for the detection of SARS-CoV-2a.

Manufacturer Test name Method Target gene Specimen type LODb Sensitivity Specificity Statusc Ref.
LumiraDx UK Ltd LumiraDx SARS-CoV-2 RNA STAR Complete RT, qSTAR amplification, home collection, screening, pooling N gene Nasal swabs 32 TCID50 per mL 97% 96% H 36
Abbott Molecular Inc. Abbott RealTime SARS-CoV-2 Assay RT-PCR N and RdRP genes Nasopharyngeal and oropharyngeal swabs 100 copies per mL 95.9% 100% H 37
Meridian Bioscience, Inc. Revogene SARS-CoV-2 RT-PCR N gene Nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swab specimens 7 TCID50 per mL 97.7% 97.7% H, M 15
Talis Biomedical Corporation Talis One COVID-19 Test System Reverse transcriptase isothermal amplification ORF1ab gene, N gene Nasal mid-turbinate swabs 500 copies per mL 100% 100% H, M, W 38
Cepheid Xpert Xpress CoV-2/Flu/RSV plus rRT-PCR N gene, E gene, RdRP genes Nasopharyngeal swabs, anterior nasal swabs, nasal wash/aspirate specimens 138 copies per mL 100% 100% H, M, W 39
Life Technologies Corporation (a part of Thermo Fisher Scientific Inc.) TaqPath COVID-19 Fast PCR Combo Kit 2.0 rRT-PCR N gene, ORF1a, ORF1b Saliva 1000 GCE per mL 97.1% 97.6% H 40
Detect, Inc. Detect Covid-19 Test RT-LAMP ORF1ab Anterior nasal swabs 800 copies per mL 90.9% 97.5% Home, H, M, W 41
PerkinElmer, Inc. PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 rRT-PCR N gene, ORF1a gene Nasopharyngeal swabs, anterior nasal swabs, and mid-turbinate swabs SARS-CoV-2: 0.11 TCID50 per mL 100% 100% H 20
LMSI, LLC (dba Lighthouse Lab Services) CovidNow SARS-CoV-2 Assay rRT-PCR N gene Upper respiratory specimens, self-collected anterior nasal swab specimens 800 copies per mL 96% 100% H 21
Applied DNA Sciences Inc. Linea COVID-19 Assay Kit rRT-PCR S gene (S1 and S2 regions) Nasopharyngeal swabs and oropharyngeal swabs 1250 copies per mL 98% 92% H 22
Enzo Life Sciences, Inc. AMPIPROBE SARS-CoV-2 Test System rRT-PCR N gene and RdRP gene Nasal, mid-turbinate, nasopharyngeal, and oropharyngeal swab specimens 280 copies per mL 96.2% 98% H 42
Thermo Fisher Scientific Inc. TaqPath COVID-19 RNase P Combo Kit 2.0 rRT-PCR N gene, ORF1a, ORF1b Nasopharyngeal, anterior, and mid-turbinate nasal swabs 75 GCE per mL 96.7% 95% H 43
Twist Bioscience Corporation SARS-CoV-2 NGS Assay NGS Several Nasopharyngeal swabs, oropharyngeal swabs, anterior nasal swabs 800 copies per mL 96.7% 100% H 44
BioGX, Inc. BioGX Xfree COVID-19 Direct RT-PCR rRT-PCR N1 gene Nasopharyngeal, anterior nasal, mid-turbinate 1000–3000 copies per mL (depending on the platform used) 95% 100% H 26
OSANG Healthcare GeneFinder COVID-19 Plus RealAmp Kit rRT-PCR RdRP, E gene, N gene Alveolar lavage fluid, throat swab, sputum 10 copies per 20 μL reaction 100% 100% H 45
OPTI Medical Systems OPTI SARS-CoV-2 RT PCR Test rRT-PCR, pooling N gene (N1 and N2) Anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal swabs 700–900 copies per mL 100% 100% H 46
PathogenDx, Inc. DetectX-Rv rRT-PCR, DNA microarray hybridization N gene (N1 and N2 regions) Nasopharyngeal swabs, oropharyngeal swabs, mid-turbinate swabs, anterior nasal swabs 1000 copies per mL 95% 100% H 47
Hologic, Inc. Aptima SARS-CoV-2 Assay Real-time TMA, dual kinetic assay ORF1ab (2 targets) Nasopharyngeal, nasal, mid-turbinate, and oropharyngeal swab specimens 212 copies per mL within a sample (83 copies per mL within the tested aliquot) 100% 98% H 48
LumiraDx UK Ltd LumiraDx SARS-CoV-2 RNA STAR Complete RT-qSTAR amplification ORF1a Mid-turbinate, nasopharyngeal, and oropharyngeal swabs 7500 copies per mL 97.8% 98.5% H 49
Quidel Corporation Solana SARS-CoV-2 Assay Molecular isothermal Reverse Transcriptase – Helicase-Dependent Amplification (RT-HDA) ORF1ab Nasopharyngeal and nasal swab specimens 1.16 ×104 copies per mL 90.3% 97.8% H, M 32
Cue Health Inc. Cue COVID-19 Test for Home and Over the Counter Use Isothermal amplification, home collection N gene Anterior nares swabs 2700 copies per mL 96% (symptomatic), (100% asymptomatic) 98% (symptomatic), (100% asymptomatic) Home, H, M, W 50
Grifols Diagnostic Solutions Inc. Procleix SARS-CoV-2 Assay Transcription-mediated nucleic acid amplification (TMA) Not stated Anterior nasal and mid-turbinate nasal swabs, nasopharyngeal 60 copies per mL 100% 100% H 51
Agena Bioscience, Inc. MassARRAY SARS-CoV-2 Panel rRT-PCR, MALDI-TOF N gene (N1, N2, and N3 regions), ORF1, and ORF1ab Nasopharyngeal swabs, oropharyngeal swabs, nasal and mid-turbinate swabs 310–2500 copies per mL 98.9% 100% H 35
Cepheid Xpert® Omni SARS-CoV-2 rRT-PCR E gene and N gene (N2 region) Nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swab specimens 400 copies per mL 100% 100% H, M, W 52
Lucira Health, Inc. Lucira COVID-19 All-In-One Test Kit RT-LAMP N gene (two regions) Nasal swab (self-collection), nasal swab (healthcare collection) 2700 copies per swab (or 900 copies per mL if the sample is 100% lysed and eluted) 94% 98% Home, H, M, W 53
GenMark Diagnostics, Inc. ePlex Respiratory Pathogen Panel 2 rRT-PCR, electrochemical detection Not stated Nasopharyngeal swabs 0.01TCID50 per mL 100% 100% H, M 54
Seasun Biomaterials, Inc. AQ-TOP COVID-19 Rapid Detection Kit PLUS RT-LAMP ORF1ab and N genes Oropharyngeal and nasopharyngeal swabs, anterior nasal and mid-turbinate nasal swabs 1000 copies per mL 100% 100% H 55
Clear Labs, Inc. Clear Dx SARS-CoV-2 Test rRT-PCR, NGS Several Nasopharyngeal swab, oropharyngeal swab, anterior nasal swab 2000 copies per mL 100% 100% H 56
Abbott Diagnostics Scarborough ID NOW COVID-19 Isothermal amplification RdRP Direct nasal secretions, nasopharyngeal or throat swabs 125 copies per mL 100% 100% H, M, W 57
Cue Health Inc. Cue COVID-19 Test Isothermal amplification N gene Nasal swab 1300 copies per mL 100% 92% Home, H, M, W 58
a

H: laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (chemiluminescence immunoassay, CLIA), 42 U.S.C. §263a, that meet requirements to perform high complexity tests. M: laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate complexity tests. W: patient care settings operating under a CLIA Certificate of Waiver.

b

LOD, Limit of detection.

c

Status, Authorized settings include the following.